Clinical aspects of platelet inhibitors and thrombus formation
TA Meadows, DL Bhatt - Circulation research, 2007 - Am Heart Assoc
The platelet, once thought to be solely involved in clot formation, is now known to be a key
mediator in various others processes such as inflammation, thrombosis, and atherosclerosis …
mediator in various others processes such as inflammation, thrombosis, and atherosclerosis …
The quantification of infarct size
RJ Gibbons, US Valeti, PA Araoz, AS Jaffe - Journal of the American …, 2004 - jacc.org
We sought to summarize the published evidence regarding the measurement of infarct size
by serum markers, technetium-99m sestamibi single-photon emission computed …
by serum markers, technetium-99m sestamibi single-photon emission computed …
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind …
G Montalescot, SD Wiviott, E Braunwald, SA Murphy… - The Lancet, 2009 - thelancet.com
Background Mechanical reperfusion with stenting for ST-elevation myocardial infarction
(STEMI) is supported by dual antiplatelet treatment with aspirin and clopidogrel. Prasugrel, a …
(STEMI) is supported by dual antiplatelet treatment with aspirin and clopidogrel. Prasugrel, a …
Guidelines for percutaneous coronary interventions: the Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology
S Silber, P Albertsson, FF Avilés… - European heart …, 2005 - academic.oup.com
In patients with stable CAD, PCI can be considered a valuable initial mode of
revascularization in all patients with objective large ischaemia in the presence of almost …
revascularization in all patients with objective large ischaemia in the presence of almost …
Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials
ContextThe benefits of abciximab in patients with ST-segment elevation myocardial
infarction (STEMI) are still a matter of debate. ObjectiveTo combine data from all randomized …
infarction (STEMI) are still a matter of debate. ObjectiveTo combine data from all randomized …
Mechanical reperfusion in patients with acute myocardial infarction presenting more than 12 hours from symptom onset: a randomized controlled trial
A Schömig, J Mehilli, D Antoniucci, G Ndrepepa… - Jama, 2005 - jamanetwork.com
ContextNo specifically designed studies have addressed the role of primary percutaneous
coronary intervention in patients with acute ST-segment elevation myocardial infarction …
coronary intervention in patients with acute ST-segment elevation myocardial infarction …
Intracoronary compared with intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary …
H Thiele, K Schindler, J Friedenberger, I Eitel… - Circulation, 2008 - Am Heart Assoc
Background—Abciximab reduces major adverse cardiac events in patients with ST-
elevation myocardial infarction undergoing primary percutaneous coronary intervention …
elevation myocardial infarction undergoing primary percutaneous coronary intervention …
Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the …
Context Abciximab infusion and uncoated-stent implantation is a complementary treatment
strategy to reduce major adverse cardiac events in patients undergoing angioplasty for ST …
strategy to reduce major adverse cardiac events in patients undergoing angioplasty for ST …
Time-to-treatment significantly affects the extent of ST-segment resolution and myocardial blush in patients with acute myocardial infarction treated by primary …
G De Luca, AWJ Van't Hof, MJ de Boer… - European Heart …, 2004 - academic.oup.com
Aims The prognostic role of time-to-treatment in primary angioplasty is still a matter of
debate. The aim of our study was to evaluate the relationship between time-to-treatment and …
debate. The aim of our study was to evaluate the relationship between time-to-treatment and …
Early vs late administration of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction: a meta …
G Montalescot, M Borentain, L Payot, JP Collet… - Jama, 2004 - jamanetwork.com
ContextGlycoprotein IIb/IIIa (Gp IIb/IIIa) inhibitors improve myocardial reperfusion and
clinical outcomes of patients undergoing primary percutaneous coronary intervention (PCI) …
clinical outcomes of patients undergoing primary percutaneous coronary intervention (PCI) …